Skip to Content
Merck
All Photos(1)

Documents

O-004

Supelco

Oxymorphone solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C17H19NO4
CAS Number:
76-41-5
Molecular Weight:
301.34
MDL number:
MFCD00079194
UNSPSC Code:
41116107
PubChem Substance ID:
329818813
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal)

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

forensics and toxicology

format

single component solution

storage temp.

2-8°C

SMILES string

CN1CC[C@]23[C@H]4Oc5c(O)ccc(C[C@@H]1[C@]2(O)CCC4=O)c35

InChI

1S/C17H19NO4/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9/h2-3,12,15,19,21H,4-8H2,1H3/t12-,15+,16+,17-/m1/s1

InChI key

UQCNKQCJZOAFTQ-ISWURRPUSA-N

Gene Information

human ... OPRD1(4985) , OPRK1(4986) , OPRM1(4988)

Looking for similar products? Visit Product Comparison Guide

General description

A certified Snap-N-Spike® solution of oxymorphone suitable for use in a variety of GC/MS or LC/MS applications from pain prescription monitoring, clinical toxicology, and pharmaceutical research to forensic analysis and urine drug testing. Oxymorphone, sold under trade names such as Opana®, Numorphan®, and Numorphone, is an opiate analgesic indicated for the relief of moderate to severe pain.

Application


  • Advanced UHPLC-MS/MS Methodology: A novel ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method has been developed for quantifying oxymorphone along with other opioids in various human tissues. This technique is crucial for understanding the pharmacokinetics and tissue distribution of synthetic opioids, providing valuable data for both clinical and pharmaceutical research (Manca et al., 2023).

  • Genetic Association Studies: Oxymorphone′s application extends to genetic studies where its interaction with the CYP2D6 genotype is analyzed to determine individual responses in opioid analgesia. This research is critical for optimizing pain management strategies and reducing adverse effects in treatments involving synthetic opioids (Merchant et al., 2022).

  • Drug Safety and Regulation: Oxymorphone is a focus of regulatory review processes, particularly in the context of the opioid crisis. Analyzing the decisions and advisories concerning oxymorphone helps in understanding its role in current medical practice and its impact on public health policies (Litman, 2020).

  • Innovative Analytical Techniques: Research includes the development of advanced analytical techniques, such as gas chromatography-mass spectrometry, for detecting oxymorphone in biological samples. These methods are essential for clinical diagnostics and forensic investigations, ensuring accurate and sensitive detection of this potent analgesic (Norouzi et al., 2020).

  • In Vitro Safety Evaluations: Oxymorphone is also studied in in vitro models to assess its hemolytic potential when abused intravenously. This research is crucial for understanding the risks associated with non-prescribed administration routes and contributes to safer pharmaceutical formulations (Persich et al., 2020).

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Numorphan is a registered trademark of Endo Pharmaceuticals Inc.
Opana is a registered trademark of Endo Pharmaceuticals Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

related product

Product No.
Description
Pricing

P-071

Pain Management Multi-component Opiate Mixture-13 solution, 100 μg/mL each component (10 μg/mL Fentanyl), ampule of 1.0 mL, certified reference material, Cerilliant®

H-098

6α/β-Hydroxyoxymorphone-D3 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-012

Noroxymorphone hydrochloride solution, 1.0 mg/mL in methanol: DMSO (80:20) (as free base), ampule of 1 mL, certified reference material, Cerilliant®

O-003

Oxymorphone-D3 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

O-019

Oxymorphone-D3 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

O-030

Oxymorphone-3-β-D-glucuronide solution, 100 μg/mL in methanol: water (1:1), ampule of 1 mL, certified reference material, Cerilliant®

O-031

Oxymorphone-D3-3-β-D-glucuronide solution, 100 μg/mL in methanol: water (1:1), ampule of 1 mL, certified reference material, Cerilliant®

O-004S

Oxymorphone solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Wuyi Zha et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 902, 116-121 (2012-07-17)
A selective high performance liquid chromatography-tandem mass spectrometric (LC-MS/MS) method for the simultaneous determination of oxymorphone and its active metabolite 6-OH-oxymorphone in human plasma was developed and validated using oxymorphone-d(3) as the internal standard. Chromatographic conditions were optimized to separate
John H Peniston et al.
Postgraduate medicine, 124(2), 114-122 (2012-03-23)
Opioids and antidepressants are frequently prescribed for chronic low back pain (cLBP). This post hoc analysis was conducted to assess the tolerability of oxymorphone extended release (ER) for cLBP in patients taking selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake
Joseph V Pergolizzi et al.
Journal of opioid management, 8(6), 383-393 (2012-12-25)
The aging population generally has greater need for analgesics and is best served by having as many good therapeutic options as possible. Geriatric analgesia requires special consideration of age-associated physiologic changes that can affect drug dosing. The study of extended-release
Marco Pappagallo et al.
Postgraduate medicine, 124(5), 101-109 (2012-10-26)
Because rates of both opioid prescribing and opioid abuse have increased, drug companies have responded by considering strategies to make opioid formulations less attractive for abuse without compromising safety or efficacy for patients with legitimate pain management needs. The emergence
M Spetea et al.
Current medicinal chemistry, 19(15), 2442-2457 (2012-03-30)
Morphine and other opioid morphinans produce analgesia primarily through μ opioid receptors (MORs), which mediate beneficial but also non-beneficial actions. There is a continued search for efficacious opioid analgesics with reduced complications. The cornerstone in the development of 14-alkoxymorphinans as
View All Related Papers

Articles

Benefits of Ascentis Express Phenyl-Hexyl over Biphenyl for the Separation of Pain Management Opiates

Although both biphenyl and phenyl-hexyl phases can resolve these compounds, the former exhibits excellent peak shape and substantially less silanol-derived ion exchange activity.

Protocols

LC/MS (TOF) Analysis of Drugs and Their Glucuronide Metabolites in Urine on Titan™ C18 after Solid Phase Extraction (SPE) using Supel™-Select SCX, β-Glucuronidase Enzyme Digestion

-THC solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material

Using UHPLC/MS (TOF) for Detection of Drugs and Metabolites in Urine Following Optimized Enzymatic Hydrolysis Conditions

To optimize hydrolysis using β-glucuronidase, factors such as incubation time, temperature, hydrolysis pH, enzyme source, and enzyme concentration must be evaluated for each glucuronide metabolite to be analyzed.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service